Andreas Evers

This inventor holds 33 USPTO granted patents and 15 published patent applications, plus 2 CIPO patents and 22 EPO patents, primarily in GLP-1 Agonists. Top assignees: Sanofi, Antaros Medical Ab, Sanofi-Aventis Recherche & Développement. Active years: 2013-2026.

USPTO Granted Patents = 33 (Patent Applications = 15)

% Patents Active = 42.4

CIPO Patents = 2 (Patent Applications = 24)

EPO Patents = 22 (Patent Applications = 38)

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 93(Granted Patents)

Location History:

Florsheim, DE (2018)
Flörsheim, DE (2018)
Frankfurt-am-Main, DE (2013 - 2021)

Company Filing History:

Sanofi-Aventis Recherche & Développement

patents

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

GLP-1 Agonists

Dual Receptor Therapies

Exendin-4 Derivatives

Macrocyclic Urea

Sulfamide Derivatives

Peptidic Agonists

Therapeutics

Chelating Moiety

Thrombus Formation

Imaging Purposes

Pharmaceuticals

Linker Conjugates

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679878 - CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY (2026-07-14),

2. 11141489 - Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid (2021-10-12),

3. 11046743 - Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes (2021-06-29),

4. 10806797 - Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate (2020-10-20),

5. 10792367 - Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid (2020-10-06),

6. 10758592 - Exendin-4 derivatives as dual GLP1/glucagon agonists (2020-09-01),

7. 10583174 - FGF21 compound / GLP-1R agonist combinations with optimized activity ratio (2020-03-10),

8. 10538567 - Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists (2020-01-21),

9. 10519211 - Compounds as peptidic GLP1/glucagon/GIP receptor agonists (2019-12-31),

10. 10253079 - Functionalized Exendin-4 derivatives (2019-04-09),

11. 9982029 - Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists (2018-05-29),

12. 9932381 - Exendin-4 derivatives as selective glucagon receptor agonists (2018-04-03),

13. 9834527 - Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals (2017-12-05),

14. 9789165 - Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists (2017-10-17),

15. 9775904 - Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists (2017-10-03),

Title: The Innovative Mind of Andreas Evers

Introduction: Andreas Evers, a pioneering inventor hailing from Frankfurt am Main, Germany, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Andreas Evers has recently been granted patents for his cutting-edge inventions in the fields of renewable energy and sustainable transportation, showcasing his commitment to creating a greener future for generations to come.

Career Highlights: With a career spanning over two decades, Andreas Evers has established himself as a leading figure in the innovation landscape, with a focus on developing solutions that address pressing global challenges. His work has not only revolutionized industries but has also earned him recognition as a visionary inventor.

Collaborations: Throughout his career, Andreas Evers has collaborated with top research institutions, universities, and forward-thinking companies to bring his inventions to life. His ability to work across disciplines and sectors has led to the successful implementation of his groundbreaking ideas.

Conclusion: Andreas Evers' passion for innovation, coupled with his relentless drive to push the boundaries of what is possible, has solidified his position as a trailblazing inventor in the world of technology. His contributions continue to inspire and shape the future of innovation.